A Comparative Evaluation of Mosapride Versus Metoclopramide for Enteral Feeding Intolerance in Critically Ill Patients

Launched by AIN SHAMS UNIVERSITY · Feb 12, 2025

Keywords

ClinConnect Summary

This clinical trial is designed to compare two medications, Mosapride and Metoclopramide, to see which one is better at helping critically ill patients tolerate enteral feeding, which is a way to provide nutrition through a tube directly into the stomach. In the intensive care unit (ICU), many patients struggle with feeding intolerance due to slow gastric emptying, which can lead to serious complications. The goal of this study is to determine which medication is more effective and safer for improving gastric motility—essentially helping the stomach empty food more quickly—so that patients can receive the nutrition they need.

To participate in this trial, patients must be between 18 and 60 years old, admitted to the ICU for at least seven days, and prescribed enteral feeding. However, those with certain health issues, such as previous stomach surgeries, serious liver problems, or specific heart conditions, will not be eligible. Participants can expect to receive one of the two medications and be monitored for any side effects or improvements in their ability to tolerate feeding. This study aims to find a better solution to improve nutrition delivery in critically ill patients, which is crucial for their recovery.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients aging between 18 and 60 years (of both sexes)
• • Patients admitted to the ICU and are expected to stay in the ICU for not less than 7 days
• • Patients prescribed enteral feeding.
• Exclusion Criteria:
• • The following patients are
• • Age less than 18 years or more than 60 years.
• • Patients who had previous upper gastrointestinal tract surgery, obstruction, hemorrhage or history of GI disease.
• • Patients who are clinically significant hepatic dysfunction. (\>3 times above the upper end of normal range of bilirubin, γ-glutamyl transferase, aspartate transaminase, or lactate dehydrogenase)
• • Patients who are on regular use of H2 blockers, prokinetic, proton pump inhibitor or anticholinergic agents for previous 4 weeks.
• • Patients with arrhythmia or atrioventricular blocks.
• • Patients with any condition or comorbid disease that might interfere with gastric emptying such as diabetes.
• • Patients with head injuries.